TCNNF - Marijuana Rescheduling Stock Market Reactions: Analyst Insights On Who Wins & Possible Trump Election | Benzinga
The anticipated shift of cannabis to Schedule III marks a pivotal moment for U.S. cannabis companies. In a detailed report, senior analyst Pablo Zuanic highlights key benefits of this change, including substantial improvements in cash flow and creditworthiness, influx of new capital, expansion prospects and growth in related industries.
The new developments include the official recommendation by the HHS to reschedule cannabis from Schedule I to Schedule III, and the Friday release of a detailed 252-page document providing a comprehensive rationale for this change, based on new data and research.
Major Catalysts For Sector Growth: Banking And Legal Implications
A major consequence of this rescheduling would be the facilitation of banking access for U.S. cannabis operators. This might render the SAFER Banking Act less critical and could lead to U.S. exchanges allowing the uplisting of U.S. plant-touching companies.
"With cannabis under Schedule III, the removal of 280E would significantly improve the cash flow picture and creditworthiness of US plant-touching companies,” Zuanic wrote. ...